ATE309200T1 - Antikonvulsive und zns-aktive bis-fluoralkylamide - Google Patents

Antikonvulsive und zns-aktive bis-fluoralkylamide

Info

Publication number
ATE309200T1
ATE309200T1 AT98963065T AT98963065T ATE309200T1 AT E309200 T1 ATE309200 T1 AT E309200T1 AT 98963065 T AT98963065 T AT 98963065T AT 98963065 T AT98963065 T AT 98963065T AT E309200 T1 ATE309200 T1 AT E309200T1
Authority
AT
Austria
Prior art keywords
disorders
diseases
compounds
epilepsy
treatment
Prior art date
Application number
AT98963065T
Other languages
English (en)
Inventor
Manuel F Balandrin
Bradford C Vanwagenen
Linda D Artman
Alan L Mueller
Daryl Smith
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE309200T1 publication Critical patent/ATE309200T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT98963065T 1997-12-10 1998-12-09 Antikonvulsive und zns-aktive bis-fluoralkylamide ATE309200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6900597P 1997-12-10 1997-12-10
PCT/US1998/026315 WO1999029657A1 (en) 1997-12-10 1998-12-09 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides

Publications (1)

Publication Number Publication Date
ATE309200T1 true ATE309200T1 (de) 2005-11-15

Family

ID=22086084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963065T ATE309200T1 (de) 1997-12-10 1998-12-09 Antikonvulsive und zns-aktive bis-fluoralkylamide

Country Status (11)

Country Link
US (2) US6617358B1 (de)
EP (1) EP1042275B1 (de)
JP (1) JP2001525390A (de)
CN (1) CN1159287C (de)
AT (1) ATE309200T1 (de)
AU (1) AU763245B2 (de)
CA (1) CA2313236A1 (de)
DE (1) DE69832302D1 (de)
IL (1) IL136306A (de)
NZ (2) NZ536524A (de)
WO (1) WO1999029657A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01004317A (es) 1998-10-30 2003-06-06 Jordan L Holtzman Un complejo de una chaperona con -amiloideo y metodos que emplean este complejo.
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
WO2001089500A2 (en) * 2000-05-24 2001-11-29 Jordan Loyal Holtzman Agents and methods for increasing brain chaperonin levels
US6399641B1 (en) * 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
US7560862B2 (en) * 2004-10-22 2009-07-14 Eastman Kodak Company White OLEDs with a color-compensated electroluminescent unit
US9212155B2 (en) * 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
CA2718723C (en) * 2008-03-19 2018-05-08 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
BRPI0921059A2 (pt) * 2008-11-14 2018-10-16 Dainippon Sumitomo Pharma Co., Ltd. derivados de bifenilacetamida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269079A (de) * 1960-09-09 1964-06-25
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
US4603145A (en) * 1983-05-06 1986-07-29 American Cyanamid Company Antiatherosclerotic diphenyl alkanamides
EP0450689A1 (de) * 1990-04-02 1991-10-09 Akzo Nobel N.V. Isochromanderivate
FR2664594B1 (fr) * 1990-07-11 1992-09-18 Adir Polymethylene-imines disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5506268A (en) 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
PT743853E (pt) * 1994-02-08 2001-10-31 Nps Pharma Inc Compostos activos num novo local em canis de calcio activados por um receptor uteis para o tratamento de perturbacoes e doencas neurologicas
AU3414295A (en) * 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
JP2002511835A (ja) * 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物

Also Published As

Publication number Publication date
NZ536524A (en) 2006-04-28
IL136306A0 (en) 2001-05-20
CN1159287C (zh) 2004-07-28
NZ524395A (en) 2004-10-29
CA2313236A1 (en) 1999-06-17
IL136306A (en) 2005-09-25
AU763245B2 (en) 2003-07-17
US20030199589A1 (en) 2003-10-23
JP2001525390A (ja) 2001-12-11
WO1999029657A1 (en) 1999-06-17
AU1817099A (en) 1999-06-28
EP1042275A1 (de) 2000-10-11
DE69832302D1 (de) 2005-12-15
US6617358B1 (en) 2003-09-09
EP1042275B1 (de) 2005-11-09
CN1284056A (zh) 2001-02-14

Similar Documents

Publication Publication Date Title
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
HUP0401567A2 (hu) CB1 receptor antagonista aktivitással rendelkező új 4,5-dihidro-1H-pirazol-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
ATE309200T1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
EA200101134A1 (ru) Одно- и двузамещенные 3-пропил-гамма-аминомасляные кислоты
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
NZ338016A (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
DE69930662D1 (de) Humane rezeptortyrosinkinase
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
EP1640359A3 (de) Antikonvulsive und zns-aktive bis-fluoroalkylamide
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
ATE384133T1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
PT973743E (pt) Composicoes farmaceuticas que incorporam compostos olefinicos de amina substituidos com arilo
TH30603A (th) สารประกอบแบบใหม่